Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Blocking Free Radicals To Prevent Age-Related Disease


Cell Culture

Despite being a normal part of cellular energetics, free radicals can cause damage to other parts of the cell, and seem to accumulate more in association with cellular stress, disease and aging.

Tweetables from this article:

Tweet: #Clinicaltrials of #antioxidants have failed to provide compelling evidence for free radical-fighting benefits http://ctt.ec/4ibNJ+ Clinical trials of antioxidants have failed to provide compelling evidence for free radical-fighting benefits.

Share this!

October 6, 2016 | by Sarah Hand, M.Sc.

Free radicals cause cellular damage, which has been implicated in many diseases associated with aging, however few truly effective treatments exist to prevent free radicals wreaking havoc on our bodies. While food and nutritional supplements often tout the benefits of antioxidants at combating free radicals, most clinical trials have failed to provide compelling evidence supporting these claims.

According to Dr. Martin Brand, a researcher at the Buck Institute for Research on Aging, in Novato, California, current free radical-fighting treatments may be too broad to have a significant impact on the reactive cellular components. “Rather than a sledgehammer that seeks to decrease the effects of free radicals, we’ve developed a scalpel that allows us to stop them from being produced in the first place,” said Brand.

The generation of free radicals occurs within the energy-producing organelles in the cell, the mitochondria. Despite being a normal part of cellular energetics, free radicals can cause damage to other parts of the cell, and seem to accumulate more in association with cellular stress, disease and aging.

As the generation of free radicals is intimately connected to the cell’s essential production of energy, the challenge for researchers has been to develop drugs that block free radical release without interfering with energy metabolism. In their search for a targeted drug capable of performing this function, Brand and his colleagues screened a library of 635,000 small molecules.

They identified a few small molecules which were targeted toward a specific site in the electron transport chain, thought to be a key producer of free radicals. The research was published in the journal, Cell Metabolism.

The researchers tested these small molecule drug candidates in cell culture, isolated hearts and living disease models. In a mouse heart model of ischemia, the compounds were able to protect the cells against reperfusion injury when the blood supply was returned to the oxygen-deprived organ.

“For the first time we can test the effects of free radical damage in Alzheimer’s, Parkinson’s, cancer, type 2 diabetes, macular degeneration – you name it,” said Brand. “It gives you a target, and a drug candidate to hit that target.

“We can start to answer questions that scientists have puzzled about for 50 years in terms of the specifics of oxidative damage. We now have a precise tool to find out if the theory is correct. We can go into a biological system, see specifically what free radicals do and take preliminary steps to stop it.”

Keywords: Cellular Damage, Age-Related Disease, Small Molecule Drug


Share this with your colleagues!

New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News

Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News

Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


Strategies for Deploying Innovative Solutions for Perimeter Security

Natural History vs. Registry Studies in Rare Disease

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act

Copyright © 2016-2017 Honeycomb Worldwide Inc.